Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00358566
Registration number
NCT00358566
Ethics application status
Date submitted
14/07/2006
Date registered
1/08/2006
Date last updated
19/05/2008
Titles & IDs
Public title
GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
Query!
Scientific title
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.
Query!
Secondary ID [1]
0
0
Eudract no. 2005-005014-21
Query!
Secondary ID [2]
0
0
PX115.1.1-302
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Unresectable Pancreatic Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Pancreatic
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Other interventions - GV1001
Treatment: Drugs - Gemcitabine (Chemotherapy)
Active Comparator: Gemcitabine - Gemcitabine alone treatment.
Experimental: GV1001 - GV1001 in sequential combination with Gemcitabine
Other interventions: GV1001
0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
Treatment: Drugs: Gemcitabine (Chemotherapy)
Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall survival time
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
12 month
Query!
Secondary outcome [1]
0
0
Progression Free Survival
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Time of progression
Query!
Eligibility
Key inclusion criteria
1. Histologically or cytologically confirmed, unresectable, locally advanced, or
metastatic adenocarcinoma of the pancreas.
2. Adequate hematological parameters:
Hemoglobin >/= 9.5 g/dL [SI units, 5.9 mmol/L] WBC >/= 3000/mm3 [SI units, >/= 3 x
109/L] Platelets >/= 100,000/mm3 [SI units, >/= 100 x 109/L]
3. Adequate baseline liver function:
Total Bilirubin < 3x ULN and
Without liver metastases:
AST (SGOT) </= 2.5 x ULN ALT (SGPT) </= 2.5 x ULN
With liver metastases:
AST (SGOT) </= 5 x ULN ALT (SGPT) </= 5 x ULN
4. Serum creatinine </= 1.5 mg/dL [SI units, 132 µmol/L].
5. Performance status ECOG 0-1.
6. Male or female 18 - 75 years inclusive.
7. Minimum life expectancy of 3 months.
8. Written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Treatment with chemotherapy for pancreatic cancer.
2. Treatment with other investigational drugs within the last 4 weeks prior to inclusion
3. Immune-suppressive therapy <4 weeks prior to inclusion
4. Chronic corticosteroid use except for asthma inhalers / topical use
5. Radiotherapy within 8 weeks of randomisation.
6. Other prior malignancies except for adequately treated non-melanoma skin cancers (BCC,
SCC) and carcinoma in situ of the cervix.
7. Known diagnosis of HIV (AIDS), Hepatitis B, C.
8. Known history of or co-existing autoimmune disease.
9. Known CNS metastases.
10. Clinically significant serious disease or organ system disease not currently
controlled on present therapy.
11. Pregnancy or lactation.
12. Women of childbearing potential not using reliable and adequate contraceptive methods*
13. Known sensitivity to any components of vaccine, gemcitabine or GM-CSF.
14. Unable for any other reason to comply with the protocol (treatment or assessments).
- Adequate contraceptive methods are defined as the use of oral, implanted,
injectable, mechanical or barrier products for the prevention of pregnancy; or
women who are practising abstinence; or where the partner is sterile, for example
a vasectomy.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/08/2008
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
360
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
St George Hospital, Department of Medical Oncology - Kogarah
Query!
Recruitment hospital [2]
0
0
Westmead Hospital, Dept. of Medical Oncology and Palliative Care - Westmead
Query!
Recruitment hospital [3]
0
0
The Townsville Hospital, Townsville Cancer Centre - Douglas
Query!
Recruitment hospital [4]
0
0
Flinders Medical Centre, Medical Oncology - Clinical Trials - Bedford Park
Query!
Recruitment hospital [5]
0
0
Dept. of Clinical Haematology / Oncology,the Queen Elizabeth Hospital - Woodville South
Query!
Recruitment hospital [6]
0
0
Royal Hobart Hospital, Centre for Clinical Research - Hobart
Query!
Recruitment hospital [7]
0
0
Box Hill Hospital, ECRU Oncology - Box Hill
Query!
Recruitment hospital [8]
0
0
The Alfred Hospital, Medical Oncology Unit - Melbourne
Query!
Recruitment hospital [9]
0
0
Fremantle Hospital, Haemtology Department - Fremantle
Query!
Recruitment hospital [10]
0
0
Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment hospital [11]
0
0
Mount Medical Centre, Perth Oncology - Perth
Query!
Recruitment hospital [12]
0
0
Royal Perth Hospital, Department of Medical Oncology - Perth
Query!
Recruitment hospital [13]
0
0
Wesley Research Institute Limited - Auchenflower Qld
Query!
Recruitment postcode(s) [1]
0
0
NSW 2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
NSW 2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
QLD 4814 - Douglas
Query!
Recruitment postcode(s) [4]
0
0
SA 5042 - Bedford Park
Query!
Recruitment postcode(s) [5]
0
0
- Woodville South
Query!
Recruitment postcode(s) [6]
0
0
TAS 7000 - Hobart
Query!
Recruitment postcode(s) [7]
0
0
VIC 3128 - Box Hill
Query!
Recruitment postcode(s) [8]
0
0
VIC 3004 - Melbourne
Query!
Recruitment postcode(s) [9]
0
0
WA 6160 - Fremantle
Query!
Recruitment postcode(s) [10]
0
0
- Nedlands
Query!
Recruitment postcode(s) [11]
0
0
WA 6000 - Perth
Query!
Recruitment postcode(s) [12]
0
0
- Auchenflower Qld
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Montana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Brussels
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Bruxelles
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Ghent
Query!
Country [16]
0
0
Denmark
Query!
State/province [16]
0
0
Herlev
Query!
Country [17]
0
0
Denmark
Query!
State/province [17]
0
0
Odense
Query!
Country [18]
0
0
Denmark
Query!
State/province [18]
0
0
Århus
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Angers Cedex 01
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Evreux
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Grenoble Cedex
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Lille
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Lorient
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Moreau
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Nantes
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Paris
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Saint Brieuc
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Saint Gregoire
Query!
Country [29]
0
0
Ireland
Query!
State/province [29]
0
0
Cork
Query!
Country [30]
0
0
Ireland
Query!
State/province [30]
0
0
Dublin
Query!
Country [31]
0
0
Italy
Query!
State/province [31]
0
0
Ancona
Query!
Country [32]
0
0
Italy
Query!
State/province [32]
0
0
Catanzaro
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Firenze
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Reggio Emilia
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Verona
Query!
Country [36]
0
0
Netherlands
Query!
State/province [36]
0
0
Amsterdam
Query!
Country [37]
0
0
Norway
Query!
State/province [37]
0
0
Bergen
Query!
Country [38]
0
0
Norway
Query!
State/province [38]
0
0
Kristiansand
Query!
Country [39]
0
0
Norway
Query!
State/province [39]
0
0
Oslo
Query!
Country [40]
0
0
Norway
Query!
State/province [40]
0
0
Tromsoe
Query!
Country [41]
0
0
Poland
Query!
State/province [41]
0
0
Bialystok
Query!
Country [42]
0
0
Poland
Query!
State/province [42]
0
0
Elblag
Query!
Country [43]
0
0
Poland
Query!
State/province [43]
0
0
Krakow
Query!
Country [44]
0
0
Poland
Query!
State/province [44]
0
0
Lodz
Query!
Country [45]
0
0
Poland
Query!
State/province [45]
0
0
Olsztyn
Query!
Country [46]
0
0
Poland
Query!
State/province [46]
0
0
Opole
Query!
Country [47]
0
0
Poland
Query!
State/province [47]
0
0
Wroclaw
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Barcelona
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Granada
Query!
Country [50]
0
0
Spain
Query!
State/province [50]
0
0
Madrid
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Malaga
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Seville
Query!
Country [53]
0
0
Sweden
Query!
State/province [53]
0
0
Goteborg
Query!
Country [54]
0
0
Sweden
Query!
State/province [54]
0
0
Lund
Query!
Country [55]
0
0
Sweden
Query!
State/province [55]
0
0
Malmö
Query!
Country [56]
0
0
Sweden
Query!
State/province [56]
0
0
Stockholm
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pharmexa A/S
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
ICON Clinical Research
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Commercial sector/Industry
Query!
Name [2]
0
0
ORION Clinical Services
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Other
Query!
Name [3]
0
0
CIRION Central Laboratory
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Other
Query!
Name [4]
0
0
Dorevitch
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Other collaborator category [5]
0
0
Other
Query!
Name [5]
0
0
Syneos Health
Query!
Address [5]
0
0
Query!
Country [5]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To investigate the efficacy of GV1001 in sequential combination with gemcitabine in locally
advanced and metastatic adenocarcinoma of the pancreas.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00358566
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Ask Aabenhus, MSc. (Pharm)
Query!
Address
0
0
Pharmexa A/S
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00358566
Download to PDF